Paclitaxel - DOR BioPharmaAlternative Names: LPE/PLP paclitaxel; Paclitaxel LPE/PLP
Latest Information Update: 28 Aug 2007
At a glance
- Originator DOR BioPharma
- Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
- Mechanism of Action Tubulin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Jun 2003 Preclinical trials in Cancer in USA (PO)